4cra: Difference between revisions
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
Description: Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design | Description: Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design | ||
[[Category: Unreleased Structures]] | |||
[[Category: Tigerstrom, A]] | |||
[[Category: Roth, R]] | |||
[[Category: Gustafsson, D]] | |||
[[Category: Nilsson, I]] | |||
[[Category: Kang, D]] | |||
[[Category: Karis, D]] | |||
[[Category: Oster, L]] | |||
[[Category: Akkaya, S]] | |||
[[Category: Olsson, T]] | |||
[[Category: Knecht, W]] | |||
[[Category: Beisel, H.G]] | |||
[[Category: Nerme, V]] | |||
[[Category: Jurva, U]] | |||
[[Category: Erixon, K]] | |||
[[Category: Fjellstrom, O]] | |||
[[Category: Eriksson, P.O]] | |||
[[Category: Redzic, A]] | |||
[[Category: Sandmark, J]] | |||